Becton Dickinson Return on Investment 2010-2022 | BDX

Current and historical return on investment (ROI) values for Becton Dickinson (BDX) over the last 10 years.
Becton Dickinson ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-06-30 $2.64B $40.18B 6.45%
2022-03-31 $2.59B $42.11B 6.35%
2021-12-31 $2.37B $40.52B 5.80%
2021-09-30 $2.80B $40.79B 6.83%
2021-06-30 $2.42B $39.84B 5.90%
2021-03-31 $2.29B $42.54B 5.54%
2020-12-31 $2.23B $40.75B 5.54%
2020-09-30 $1.48B $40.99B 3.76%
2020-06-30 $1.34B $41.11B 3.43%
2020-03-31 $1.61B $37.76B 4.16%
2019-12-31 $1.38B $38.15B 3.53%
2019-09-30 $1.76B $39.16B 4.49%
2019-06-30 $2.22B $39.51B 5.65%
2019-03-31 $2.11B $38.87B 5.28%
2018-12-31 $2.16B $39.22B 5.25%
2018-09-30 $1.51B $39.89B 3.58%
2018-06-30 $1.42B $41.71B 3.55%
2018-03-31 $0.69B $43.74B 1.84%
2017-12-31 $0.95B $43.34B 3.08%
2017-09-30 $1.52B $31.62B 6.31%
2017-06-30 $1.13B $31.15B 5.44%
2017-03-31 $1.87B $17.05B 10.61%
2016-12-31 $1.89B $16.63B 10.50%
2016-09-30 $1.43B $18.18B 7.79%
2016-06-30 $1.63B $18.59B 8.83%
2016-03-31 $1.25B $18.53B 6.77%
2015-12-31 $1.08B $18.08B 5.78%
2015-09-30 $1.07B $18.53B 6.01%
2015-06-30 $1.18B $18.62B 7.65%
2015-03-31 $1.49B $19.29B 11.40%
2014-12-31 $1.58B $15.01B 15.00%
2014-09-30 $1.61B $8.82B 17.90%
2014-06-30 $1.28B $9.15B 14.29%
2014-03-31 $1.24B $9.08B 14.10%
2013-12-31 $1.24B $8.84B 14.40%
2013-09-30 $1.26B $8.81B 14.82%
2013-06-30 $1.57B $8.48B 19.02%
2013-03-31 $1.61B $8.35B 19.84%
2012-12-31 $1.61B $8.23B 19.81%
2012-09-30 $1.56B $7.90B 18.87%
2012-06-30 $1.53B $8.00B 18.90%
2012-03-31 $1.53B $8.44B 19.00%
2011-12-31 $1.59B $8.70B 20.24%
2011-09-30 $1.66B $7.31B 22.16%
2011-06-30 $1.62B $7.78B 21.79%
2011-03-31 $1.59B $7.58B 22.33%
2010-12-31 $1.57B $7.36B 22.71%
2010-09-30 $1.58B $6.93B 23.48%
2010-06-30 $1.65B $6.65B 24.69%
2010-03-31 $1.66B $6.64B 24.78%
2009-12-31 $1.60B $6.75B 25.01%
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $65.121B $20.248B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $49.080B 14.25
AmerisourceBergen (ABC) United States $28.071B 12.53
Laboratory Of America Holdings (LH) United States $19.156B 8.38
West Pharmaceutical Services (WST) United States $18.245B 27.78
Cardinal Health (CAH) United States $18.043B 13.09
Cooper (COO) United States $13.018B 20.37
CONMED (CNMD) United States $2.370B 23.36
Invacare (IVC) United States $0.030B 0.00